Core Viewpoint - Shanghai Pharmaceuticals has successfully included its amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective January 1, 2026, which is expected to enhance market share and competitiveness [1] Group 1: Company Information - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has obtained the listing rights for amisulpride orally disintegrating tablets [1] - The amisulpride orally disintegrating tablets are a modified formulation of the amisulpride tablets launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched amisulpride orally disintegrating tablets [1] Group 2: Market Impact - The inclusion of amisulpride orally disintegrating tablets in the National Medical Insurance Directory is expected to expand the product's market share and improve its competitive position [1] - According to the IQVIA database, the hospital procurement amount for amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1] - The successful negotiation for inclusion in the insurance directory will provide valuable experience for the company in promoting other products [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are a modified formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the date of the announcement, there are no other companies in China that have listed Amisulpride orally disintegrating tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Zhongxi, has successfully negotiated for the inclusion of Amisulpride orally disintegrating tablets in the National Medical Insurance Directory [1] Group 1: Company Information - The Amisulpride orally disintegrating tablets are an improved formulation of the Amisulpride tablets launched by Sanofi in France in 1986 [1] - The drug is indicated for the treatment of adult schizophrenia [1] Group 2: Industry Impact - The inclusion of Amisulpride in the National Medical Insurance Directory may enhance its market accessibility and potentially increase sales [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] Group 1: Company Developments - The marketing authorization holder for Amisulpride Orally Disintegrating Tablets has been officially changed to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] - The company submitted the registration application for the change of marketing authorization holder to the National Medical Products Administration in September 2025, which has been accepted [1] - The company has invested approximately 31.5 million yuan in the development of this drug as of the date of the announcement [1] Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]